Clinical TrialsSearch results
Number of results: 911
Completed
- A Phase 2 study of concurrent combination therapy of TFTD (TAS-102) and bevacizumab in patients of more than 70 years of age with unresectable, advanced/recurrent colorectal cancer (KSCC 1602)
- Colorectal Cancer
- Oki Eiji
- 2019-03-20
Other
- A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Joseph Nacson
- 2023-02-12
Completed
- A phase 2 study of osimertinib in elderly patients with non-small-cell lung cancer
- advanced / recurrent non-small cell lung cancer (NSCLC)
- Uchino Junji
- 2018-09-03
Completed
- A Phase 2 study to assess the safety, immunogenicity and recommended dose of DS-5670a in Japanese healthy adults
- Prevention of infectious disease by Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)
- Inoguchi Akihiro
- 2021-10-29
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Metformin
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Sulfonylurea
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Thiazolidine
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2008-10-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to an Alpha-Glucosidase Inhibitor
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2008-10-01
Other
- A Phase 3 Study of ALXN2060 in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Ishioka Tatsunari
- 2020-12-04
Other
- A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
- Primary Immune Thrombocytopenia
- Gandini Domenica
- 2021-10-29